Abviva to receive patent for its new Mammastatin technology
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks
More... |
All times are GMT -7. The time now is 10:11 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021